NDA Submitted for Fixed-Dose Alogliptin/Metformin for Type 2 Diabetes

Takeda announced that it has submitted a New Drug Application (NDA) to the FDA for the fixed-dose combination therapy alogliptin/metformin, which combines alogliptin with metformin in a single tablet, for the treatment of patients with type 2 diabetes.

Alogliptin is a selective dipeptidyl peptidase IV inhibitor (DPP-4i) under investigation in the U.S. for the treatment of type 2 diabetes as an adjunct to diet and exercise. Alogliptin is designed to slow the inactivation of incretin hormones GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic peptide), which play roles in regulating blood-glucose levels. Metformin is a diabetes medication that acts primarily by reducing the amount of glucose produced by the liver.

For more information call (224) 554-6500 or visit www.takeda.com.